194 related articles for article (PubMed ID: 8783661)
1. Amifostine: the preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies.
Capizzi R
Semin Oncol; 1996 Aug; 23(4 Suppl 8):2-17. PubMed ID: 8783661
[TBL] [Abstract][Full Text] [Related]
2. The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine.
Capizzi RL
Semin Oncol; 1999 Apr; 26(2 Suppl 7):3-21. PubMed ID: 10348255
[TBL] [Abstract][Full Text] [Related]
3. The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine (Ethyol).
Capizzi RL
Eur J Cancer; 1996; 32A Suppl 4():S5-16. PubMed ID: 8976816
[TBL] [Abstract][Full Text] [Related]
4. Amifostine-mediated protection of normal bone marrow from cytotoxic chemotherapy.
Capizzi RL; Scheffler BJ; Schein PS
Cancer; 1993 Dec; 72(11 Suppl):3495-501. PubMed ID: 8242582
[TBL] [Abstract][Full Text] [Related]
5. The potential of amifostine: from cytoprotectant to therapeutic agent.
Santini V; Giles FJ
Haematologica; 1999 Nov; 84(11):1035-42. PubMed ID: 10553165
[TBL] [Abstract][Full Text] [Related]
6. Guidelines for the administration of amifostine.
Schuchter LM
Semin Oncol; 1996 Aug; 23(4 Suppl 8):40-3. PubMed ID: 8783665
[TBL] [Abstract][Full Text] [Related]
7. Amifostine: is there evidence of tumor protection?
Koukourakis MI
Semin Oncol; 2003 Dec; 30(6 Suppl 18):18-30. PubMed ID: 14727237
[TBL] [Abstract][Full Text] [Related]
8. Amifostine in clinical oncology: current use and future applications.
Koukourakis MI
Anticancer Drugs; 2002 Mar; 13(3):181-209. PubMed ID: 11984063
[TBL] [Abstract][Full Text] [Related]
9. Amifostine protects primitive hematopoietic progenitors against chemotherapy cytotoxicity.
List AF; Heaton R; Glinsmann-Gibson B; Capizzi RL
Semin Oncol; 1996 Aug; 23(4 Suppl 8):58-63. PubMed ID: 8783669
[TBL] [Abstract][Full Text] [Related]
10. Amifostine: A selective cytoprotective agent of normal tissues from chemo-radiotherapy induced toxicity (Review).
Orditura M; De Vita F; Roscigno A; Infusino S; Auriemma A; Iodice P; Ciaramella F; Abbate G; Catalano G
Oncol Rep; 1999; 6(6):1357-62. PubMed ID: 10523712
[TBL] [Abstract][Full Text] [Related]
11. Protection of normal tissues from radiation and cytotoxic therapy: the development of amifostine.
Castiglione F; Dalla Mola A; Porcile G
Tumori; 1999; 85(2):85-91. PubMed ID: 10363072
[TBL] [Abstract][Full Text] [Related]
12. Disposition of WR-1065 in the liver of tumor-bearing rats following regional vs systemic administration of amifostine.
Levi M; DeRemer SJ; Dou C; Ensminger WD; Smith DE
Biopharm Drug Dispos; 2004 Jan; 25(1):27-35. PubMed ID: 14716750
[TBL] [Abstract][Full Text] [Related]
13. Amifostine (WR-2721), a cytoprotective agent during high-dose cyclophosphamide treatment of non-Hodgkin's lymphomas: a phase II study.
De Souza CA; Santini G; Marino G; Nati S; Congiu AM; Vigorito AC; Damasio E
Braz J Med Biol Res; 2000 Jul; 33(7):791-8. PubMed ID: 10881054
[TBL] [Abstract][Full Text] [Related]
14. Radioprotectants: pharmacology and clinical applications of amifostine.
Dorr RT
Semin Radiat Oncol; 1998 Oct; 8(4 Suppl 1):10-3. PubMed ID: 9794995
[TBL] [Abstract][Full Text] [Related]
15. Protection of normal tissues from the cytotoxic effects of chemotherapy and radiation by amifostine (WR-2721): preclinical aspects.
Peters GJ; van der Vijgh WJ
Eur J Cancer; 1995; 31A Suppl 1():S1-7. PubMed ID: 7577093
[TBL] [Abstract][Full Text] [Related]
16. Down-regulation of intestinal-type alkaline phosphatase in the tumor vasculature and stroma provides a strong basis for explaining amifostine selectivity.
Giatromanolaki A; Sivridis E; Maltezos E; Koukourakis MI
Semin Oncol; 2002 Dec; 29(6 Suppl 19):14-21. PubMed ID: 12577238
[TBL] [Abstract][Full Text] [Related]
17. Amifostine: potential for clinically useful cytoprotection.
Budd GT; Lorenzi V; Ganapathi R; Adelstein D; Pelley R; Olencki T; McLain D; Bukowski RM
Support Care Cancer; 1994 Nov; 2(6):380-4. PubMed ID: 7858931
[TBL] [Abstract][Full Text] [Related]
18. Amifostine: chemotherapeutic and radiotherapeutic protective effects.
Santini V
Expert Opin Pharmacother; 2001 Mar; 2(3):479-89. PubMed ID: 11336600
[TBL] [Abstract][Full Text] [Related]
19. [Amifostine: current and future applications in cytoprotection].
Lenoble M
Bull Cancer; 1996 Sep; 83(9):773-87. PubMed ID: 8952658
[TBL] [Abstract][Full Text] [Related]
20. A risk-benefit assessment of amifostine in cytoprotection.
Mabro M; Faivre S; Raymond E
Drug Saf; 1999 Nov; 21(5):367-87. PubMed ID: 10554052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
